TABLE 8

Compounds in development with novel targets or indications

Indication and compoundTypeDevelopment StageCompany
Depression
    VilazodoneSERT inhibitor; 5-HT1A agonistPhase IIIMerck
    Lu AA21004SERT inhibitor; 5-HT1A agonist; 5-HT3 antagonistPhase IIIH. Lundbeck A/S
    Lu AA24530SERT inhibitor; 5-HT2C agonist; 5-HT3 antagonistPhase IIIH. Lundbeck A/S
Premature ejaculation
    DapoxetineSSRILaunchedJohnson and Johnson
Schizophrenia
    RG1678GLYT1 inhibitorPhase IIRoche
Obesity
    Bupropion; naltrexoneNET/DAT inhibitor; opioid receptor antagonistPhase IIIOrexigen
    Bupropion; zonisamideNET/DAT inhibitor; SERT/DAT inhibitorPhase IIOrexigen
    TesofensineSERT/NET/DAT inhibitorPhase IINeuroSearch A/S
Pain
    BicifadineSNRIPhase IIDOV Pharmaceutical
    Xen2174NRIPhase IIXenome